Clinical trial · no report yet · Phase 3
MajesTEC-4
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- NCT05243797 ↗
- Recruiting
- European Myeloma Network B.V.
- 42 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 21 | |
| Podcasts | 11 | |
| YouTube | 10 |
The trial
ClinicalTrials.gov- Official title
- Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Teclistamab; Lenalidomide
- Arms
- Arm A: Teclistamab-Lenalidomide (Tec-Len) · Experimental
- Arm B Lenalidomide Alone (Len) · Active comparator
- Arm C Teclistamab-Alone (Tec) · Experimental
- Enrollment
- 1,594 (estimated)
- Primary outcomes
- Progression Free Survival (PFS)
- Minimal Residual Disease (MRD)-negative Complete Response (CR)
- Sponsor
- European Myeloma Network B.V. with Janssen Pharmaceutica
- Start
- Sep 8, 2022
- Primary completion
- Apr 2028 (estimated)
- Results posted
- No
- Registry record
- NCT05243797 · updated Oct 7, 2026